NCT05253131 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05253131
Title	Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas
Recruitment	Not yet recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	University of Alabama at Birmingham
Indications	desmoplastic small round cell tumor malignant fibrous histiocytoma osteosarcoma neurofibroma malignant peripheral nerve sheath tumor Ewing sarcoma sarcoma synovial sarcoma bone sarcoma rhabdomyosarcoma
Therapies	AZD5153 + Durvalumab + Selumetinib AZD5153 + Selumetinib
Age Groups:	senior \| adult
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
The University of Alabama at Birmingham		Birmingham	Alabama	35294	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT05253131Clinical Trial Detail